Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Fingolimod Impedes Schwann Cell-Mediated Myelination: Implications for the Treatment of Immune Neuropathies?Effect of Fingolimod on Schwann Cells.
Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vitamin D receptor.
Chronic cladribine administration increases amyloid Beta Peptide generation and plaque burden in mice.
Phase 4 GI Tolerability Study of DMF in Patients With Relapsing Forms of MS in the US (MANAGE)
Efficacy and safety study of RPC1063 in relapsing multiple sclerosis patients
Antigen-specific tolerance by autologous myelin Peptide-coupled cells: a phase 1 trial in multiple sclerosis.
Brain Volume Loss during the First Year of Interferon-Beta Treatment: Baseline Inflammation and Tissue-Specific Volume Dynamics.
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
Ustekinumab success in refractory Crohn’s disease
Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis.
[The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.
EMD Serono
Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis.
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.
Gait Mechanics are Different between Healthy Controls and Patients with Multiple Sclerosis.
Withdrawal of the marketing authorization in the European Union
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Clinically feasible MTR is sensitive to cortical demyelination in MS.
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
The Relative Importance of Baseline Pain, Fatigue, Sleep and Physical Activity: Predicting Change in Depression in Adults with Multiple Sclerosis.
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.

Pages